Emerging immunotherapies and targeted therapies take aim at recently identified biomarkers ...

Amgen’s bad luck in lupus may finally be coming to an end. Daxdilimab, a monoclonal antibody acquired from Horizon ...

Immunotherapy, targeted treatments, HIPEC, and new delivery options ...

AstraZeneca receives CDSCO approval for Durvalumab, enhancing treatment options for resectable gastric cancer in India.

February 2026 Imfinzi perioperative regimen recommended for approval in the EU by CHMP for patients with early gastric and gastroesophageal cancers Recommendation based on MATTERHORN Phase III trial ...

Elevar on Jan. 23, 2026, submitted the NDA for rivoceranib, while Hengrui Pharma submitted a biologics license application (BLA) for camrelizumab. The FDA will review the applications under an ...

Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have ...

Daiichi Sankyo & AstraZeneca’s Enhertu approved in China as first and only HER2 directed ADC for second-line treatment of patients with HER2 positive metastatic gastric cancer ...

The FDA has accepted and granted Priority Review for DATROWAY, co-developed by AstraZeneca (LSE:AZN) and Daiichi Sankyo, as a first-line treatment for certain patients with metastatic triple-negative ...

Advanced gastroesophageal adenocarcinoma (GEA) with HER2 positivity has long presented significant treatment challenges, with ...

Akeso, Inc. (9926.HK) announced the presentation of a real-world study at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO G I), comparing cadonilimab ...

Priority Review was granted by FDA for the first line metastatic TNBC treatment. Datroway significantly improved survival ...